Literature DB >> 34656034

Population-based estimates of geographic accessibility of medication for opioid use disorder by substance use disorder treatment facilities from 2014 to 2020.

Jonathan Cantor1, David Powell2, Aaron Kofner2, Bradley D Stein3.   

Abstract

BACKGROUND: Understanding whether individuals have geographic accessibility to a substance use disorder treatment facility and a treatment facility that offers medication treatment for opioid use disorder (MOUD) can inform efforts to address the ongoing opioid crisis.
METHODS: We used data from the National Directory of Drug and Alcohol Abuse Treatment Programs. First, we calculate the national share of treatment facilities that offer one type of MOUD or all forms of MOUD using a novel dataset of providers. Second, we quantify the share of counties with a treatment facility offering at least one type of MOUD. Finally, we calculate the share of the national population residing within a 10-mile radius of a treatment facility.
RESULTS: The share of counties with a treatment facility offering a MOUD as a form of treatment rose from 30% to 45% from 2014 to 2020 while the share of counties with facilities offering all three forms of MOUD increased from 4% to 9%. Over 83% of the population lives within 10 miles of a facility offering MOUD treatment, and 42% of the population have a treatment facility that offers all three forms of MOUD within a 10-mile radius. Much of the difference between the county- and population-based measures is explained by more population dense areas having higher rates of facilities providing MOUD.
CONCLUSIONS: While the share of facilities within a county offering a MOUD is relatively small, the share of the population within 10 miles of such a facility is higher.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Access to care; Medications for opioid use disorder

Mesh:

Substances:

Year:  2021        PMID: 34656034      PMCID: PMC8981564          DOI: 10.1016/j.drugalcdep.2021.109107

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  37 in total

1.  Impact Of Long-Term Buprenorphine Treatment On Adverse Health Care Outcomes In Medicaid.

Authors:  Hillary Samples; Arthur Robin Williams; Stephen Crystal; Mark Olfson
Journal:  Health Aff (Millwood)       Date:  2020-05       Impact factor: 6.301

2.  Medication-assisted therapies--tackling the opioid-overdose epidemic.

Authors:  Nora D Volkow; Thomas R Frieden; Pamela S Hyde; Stephen S Cha
Journal:  N Engl J Med       Date:  2014-04-23       Impact factor: 91.245

3.  Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.

Authors:  Sarah E Wakeman; Marc R Larochelle; Omid Ameli; Christine E Chaisson; Jeffrey Thomas McPheeters; William H Crown; Francisca Azocar; Darshak M Sanghavi
Journal:  JAMA Netw Open       Date:  2020-02-05

4.  Therapies Offered at Residential Addiction Treatment Programs in the United States.

Authors:  Tamara Beetham; Brendan Saloner; Marema Gaye; Sarah E Wakeman; Richard G Frank; Michael L Barnett
Journal:  JAMA       Date:  2020-08-25       Impact factor: 56.272

5.  Prescribing patterns of buprenorphine waivered physicians.

Authors:  Cindy Parks Thomas; Erin Doyle; Peter W Kreiner; Christopher M Jones; Joel Dubenitz; Alexis Horan; Bradley D Stein
Journal:  Drug Alcohol Depend       Date:  2017-10-18       Impact factor: 4.492

6.  Geographic access to buprenorphine prescribers for patients who use public transit.

Authors:  C Drake; J M Donohue; D Nagy; C Mair; K L Kraemer; D J Wallace
Journal:  J Subst Abuse Treat       Date:  2020-08-05

7.  Expanding access to methadone treatment in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling analysis.

Authors:  Suzan Iloglu; Paul J Joudrey; Emily A Wang; Thomas A Thornhill; Gregg Gonsalves
Journal:  Drug Alcohol Depend       Date:  2021-01-19       Impact factor: 4.492

8.  State policy influence on the early diffusion of buprenorphine in community treatment programs.

Authors:  Lori J Ducharme; Amanda J Abraham
Journal:  Subst Abuse Treat Prev Policy       Date:  2008-06-20

9.  Association of Pregnancy and Insurance Status With Treatment Access for Opioid Use Disorder.

Authors:  Stephen W Patrick; Michael R Richards; William D Dupont; Elizabeth McNeer; Melinda B Buntin; Peter R Martin; Matthew M Davis; Corey S Davis; Katherine E Hartmann; Ashley A Leech; Kim S Lovell; Bradley D Stein; William O Cooper
Journal:  JAMA Netw Open       Date:  2020-08-03

10.  An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19.

Authors:  G Caleb Alexander; Kenneth B Stoller; Rebecca L Haffajee; Brendan Saloner
Journal:  Ann Intern Med       Date:  2020-04-02       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.